Nuvation Bio Inc. (NYSE:NUVB) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.00.

Several research firms have recently commented on NUVB. Cantor Fitzgerald started coverage on shares of Nuvation Bio in a report on Friday, August 21st. They issued an “overweight” rating for the company. B. Riley Financial reaffirmed a “buy” rating on shares of Nuvation Bio in a research report on Friday, August 7th. Wall Street Zen downgraded shares of Nuvation Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a research note on Monday, October 19th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $10.00 price objective on shares of Nuvation Bio in a report on Wednesday, September 16th.

Check Out Our Latest Analysis on Nuvation Bio

Institutional Trading of Nuvation Bio

Several hedge funds and other institutional investors have recently bought and sold shares of NUVB. Goldman Sachs Group Inc. lifted its stake in shares of Nuvation Bio by 136.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,511,958 shares of the company’s stock worth $25,267,000 after purchasing an additional 2,607,272 shares during the last quarter. First Trust Advisors LP boosted its position in Nuvation Bio by 19.7% during the third quarter. First Trust Advisors LP now owns 1,558,880 shares of the company’s stock valued at $8,730,000 after purchasing an additional 256,543 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Nuvation Bio by 75.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company’s stock valued at $6,175,000 after purchasing an additional 619,725 shares in the last quarter. NewEdge Advisors LLC boosted its position in Nuvation Bio by 19.5% during the second quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company’s stock valued at $6,996,000 after purchasing an additional 200,621 shares in the last quarter. Finally, Tanaka Capital Management Inc. grew its stake in Nuvation Bio by 7.2% in the first quarter. Tanaka Capital Management Inc. now owns 901,825 shares of the company’s stock valued at $3,869,000 after purchasing an additional 60,220 shares during the last quarter. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Stock Performance

NUVB stock opened at $3.79 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 7.45 and a quick ratio of 7.30. The business has a 50-day moving average price of $4.96 and a 200 day moving average price of $5.31. The company has a market capitalization of $1.34 billion, a P/E ratio of -9.46 and a beta of 1.73. Nuvation Bio has a 1-year low of $3.77 and a 1-year high of $9.75.

Nuvation Bio (NYSE:NUVB – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $34.39 million. As a group, equities research analysts forecast that Nuvation Bio will post -0.37 EPS for the current fiscal year.

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

Featured Stories

Analyst Recommendations for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.